Autolus Therapeutics Plc Adr (AUTL)

Autolus Therapeutics Plc Adr stock is traded at $1.24, with a volume of 3,847,312. It is down -6.44% in the last 24 hours and down -29.02% over the past month. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.